A recent study (F de Benedetti et al. NEJM 2018; 378: 1908-19) presents data on canakinumab, an anti-interleukin-1β monoclonal antibody, for three hereditary periodic fever syndromes in the so-called “CLUSTER” trial.  Canakimumab is administered as a subcutaneous injection. The three periodic fevers were the following:

• Familial Mediterranean Fever (colchicine-resistant)
• Mevalonate kinase
• Tumor necrosis factor-receptor-associated periodic syndrome (TRAPS)